Impact of Immunosuppression on Acute Left Ventricular Function Recovery and ECMO Use in Patients with Fulminant Viral Myocarditis: An “All-In” Strategy

Fulminant viral myocarditis (FVM) is a rare cause of cardiogenic shock due to severe myocardial inflammation induced by inappropriately activated immune system. For years, a biased study with 15 patients has maintained the myth that FVM has an excellent prognosis but recent literature clearly shows a high morbidity with need for mechanical circulatory support (MCS) up to 60% and mortality rates between 12 to 45%. Owing to this high mortality, acute immunosuppressive therapy for FVM gained in popularity and was described in numerous retrospective studies, with a combined overall mortality under 5%.

Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: P.Y. Turgeon, M. Massot, F. Beaupr é, D. Belzile, M. Sénéchal Tags: (110) Source Type: research